Neurotrope Inc. (NTRP)
Symbol Info
Listed Symbol NTRP
Name Neurotrope Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-1.37
Price Info
21 Day Moving Average $3.1595
21 Day EMA $2.606620
50 Day Moving Average $4.6026
50 Day EMA $4.142900
200 Day EMA $5.628810
200 Day Moving Average 5.251810
52 Week High $9.24
52 Week Low $0.78
52 Week Change $-90.561800
Alpha -0.015618
Beta 2.0832
Standard Deviation 0.281047
R2 0.065134
Periods 60
Share Information
10 Day Average Volume 1,327,943
20 Day Average Volume 771,387
30 Day Average Volume 548,980
50 Day Average Volume 382,044
Outstanding Shares 13,021,542
Float Shares 13,016,699
Percent Float 99.96%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 47
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 398,531
Institute Holdings Percent 18.800000
Institute Sold Previous 3 Months 147,050
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,843
Price Change
7 Day Price Change $-0.04
7 Day Percent Change -4.55%
21 Day Price Change $-4.47
21 Day Percent Change -84.18%
30 Day Price Change $-4.805
30 Day Percent Change -85.12%
Month To Date Price Change $-4.47
Month To Date Percent -84.18%
90 Day Price Change $-6.56
90 Day Percent Change -88.65%
Quarter To Date $-7.18
Quarter To Date Percent -89.53%
180 Day Price Change $-3.44
180 Day Percent Change -80.37%
200 Day Price Change $-3.52
200 Day Percent Change -80.73%
Year To Date $-2.73
Year To Date Percent -76.47%
Profile
Description Neurotrope Inc is a biopharmaceutical company. The company is principally focused on developing a product platform based on a drug candidate called bryostatin for the treatment of Alzheimer's disease ("AD"), which is in the clinical testing stage. It is also developing bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C, which are in pre-clinical testing.
Details
Issue Type CS
Market Cap $10,938,095
Sec Type EQS
Auditor Friedman LLP
Total Shares Outstanding 13,021,542
CEO Charles S. Ryan
Employees 8
Last Audit UQ
Classification
CIK 0001513856
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1185 Avenue of the Americas
3rd Floor
New York, NY 10036
Website https://www.neurotrope.com
Facisimile
Telephone +1 973 242-0005
Email
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-9,861,668
Price To Sales -
Price To Free Cash -1
PE High Last 5 Years -
Price To Book 0.5
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.5
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 25.9
Leverage Ratio 1.1
Quick Ratio 24.9
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -89
Return On Equity -94.22
Return On Capital -95.93
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
NTRP
Neurotrope
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.